BOSTON, Sept. 27, 2023 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule allosteric therapies targeting regulatory sites on proteins referred to as 'natural hotspots,' today announced it will present additional preclinical data from the Company's CBL-B program in a poster presentation at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting, taking place November 1-5, 2023, in San Diego, CA..

波士顿，2023年9月27日/PRNewswire/-HotSpot Therapeutics，Inc.，一家生物技术公司，致力于发现和开发针对被称为“自然热点”的蛋白质调控位点的口服小分子变构疗法，“今天宣布，它将在2023年11月1日至5日在加利福尼亚州圣地亚哥举行的2023年癌症免疫治疗学会（SITC）年会上的海报展示中展示该公司CBL-B计划的其他临床前数据。。

Presentation details are as follows:

演示详情如下：

Title: Exploring Proximal Biomarkers of CBL-B Inhibition in Human Peripheral Blood Mononuclear CellsSession Date and Time: Fri., Nov. 3, 9:00 AM-7:00 PM PTLocation: Exhibit Halls A and B1, San Diego Convention Center

题目：探索人外周血单个核细胞中CBL-B抑制的近端生物标志物会议日期和时间：Fri。，11月3日上午9:00至下午7:00 PTLocation：圣地亚哥会议中心展览厅A大厅和B1大厅

Abstract Number: 55

摘要编号：55

About HST-1011HST-1011 is an investigational orally bioavailable, selective, small molecule allosteric inhibitor of CBL-B, an E3 ubiquitin protein ligase critically involved in immune cell response. Because CBL-B functions as a master regulator of effector cell (T cell and natural killer cell) immunity, its inactivation removes its endogenous negative regulatory functions to substantially enhance anti-tumor immunity.

关于HST-1011HST-1011是CBL-B的研究性口服生物可利用的选择性小分子变构抑制剂，CBL-B是一种关键参与免疫细胞应答的E3泛素蛋白连接酶。由于CBL-B充当效应细胞（T细胞和自然杀伤细胞）免疫的主要调节剂，因此其失活消除了其内源性负调节功能，从而大大增强了抗肿瘤免疫力。

Preclinical data has demonstrated HST-1011's ability to bind to and inhibit a natural hotspot on CBL-B, yielding the activation and propagation of a targeted anti-tumor immune response. Enabled by HotSpot's proprietary Smart Allostery™ platform, HST-1011 is designed with tight binding, low nanomolar potency, a slow dissociation rate from the target to enable sustained pharmacology, and greater selectivity for CBL-B relative to C-CBL..

临床前数据表明，HST-1011能够结合并抑制CBL-B上的天然热点，从而激活和传播靶向的抗肿瘤免疫应答。由HotSpot专有的智能变构启用™ 平台，HST-1011设计具有紧密结合，低纳摩尔效能，与靶标的缓慢解离速率以实现持续的药理学，以及相对于C-CBL对CBL-B的更高选择性。。

About HotSpot Therapeutics, Inc.HotSpot Therapeutics, Inc. is pioneering a new class of allosteric drugs that target certain naturally occurring pockets on proteins called 'natural hotspots.' These pockets are decisive in controlling a protein's cellular function and have significant potential for new drug discovery by enabling the systematic design of potent and selective small molecules with novel pharmacology.

关于HotSpot Therapeutics，Inc.HotSpot Therapeutics，Inc。正在开创一类新的变构药物，其靶向称为“天然热点”的蛋白质上的某些天然存在的口袋这些口袋对于控制蛋白质的细胞功能具有决定性作用，并且通过使用新药理学系统设计有效和选择性的小分子，具有显着的新药发现潜力。

The Company's proprietary Smart Allostery™ platform combines computational approaches and AI-driven data mining of large and diverse data sets to uncover hotspots with tailored pharmacology toolkits and bespoke chemistry to drive the rapid discovery of novel hotspot-targeted small molecules. Leveraging this approach, HotSpot is building a broad pipeline of novel allosteric therapies for the treatment of cancer and autoimmune diseases.

该公司专有的智能手机™ 该平台结合了计算方法和AI驱动的大型多样化数据集数据挖掘，通过量身定制的药理学工具包和定制化学方法揭示热点，以推动快速发现新型热点靶向小分子。利用这种方法，HotSpot正在建立广泛的新型变构疗法管道，用于治疗癌症和自身免疫性疾病。

To learn more, visit www.hotspotthera.com..

To learn more, visit www.hotspotthera.com..

Investor & Media Contact:Natalie Wildenradt[email protected]

投资者和媒体联系人：Natalie Wildenradt[电子邮件保护]

SOURCE HotSpot Therapeutics

源热点疗法